Regeneron Pharmaceuticals

Businessman climbing steps to pluck a star from the sky
Biotech

Regeneron's ultrarare disease phase 3 hits, teeing up filings

The biotech plans to file for FDA approval of garetosmab in FOP by the end of 2025 on the strength of a pivotal trial that read out Wednesday.
Nick Paul Taylor Sep 17, 2025 9:31am
Cat

Regeneron antibodies post ph. 3 wins against cat, pollen allergy

Sep 8, 2025 9:54am
dominoes stop stall halt end red

'Several concerning observations': FDA sheds light on rejections

Sep 5, 2025 10:45am
Focus magnify target strategy

Nykode bets future on cancer trial after losing Genentech pact

Aug 27, 2025 8:25am
Businessman climbing steps to pluck a star from the sky

Regeneron posts phase 3 win, advancing push to muscle in on gMG

Aug 26, 2025 9:41am
finance numbers tape money

Regeneron pens $2B pact for Hansoh's potential rival to Zepbound

Jun 2, 2025 8:20am